2026-09268NoticeWallet

FDA's New Rules: Checking if Pills Play Nice with Pregnancies

Published Date: 5/11/2026

Notice

Summary

The FDA just released final guidance to help drug makers study how their medicines affect pregnant women after approval. This update affects companies and researchers who must now follow clearer steps to check pregnancy safety, helping protect moms and babies. The guidance is effective immediately, with no new costs announced, but it encourages better, safer studies going forward.

Free Policy Watch

New rules are filed every week. Most people never see them.

Pick a topic. PRIA watches every federal rule and tells you when one hits your household.

Pick a topic to get started

Analyzed Economic Effects

3 provisions identified: 3 benefits, 0 costs, 0 mixed.

New Method Guidance: Registries & Rare Exposures

The final guidance updates methods for postapproval pregnancy safety work by clarifying the pregnancy registry section (including a new statistical methods subsection), broadening complementary study methods, expanding discussion on collecting data when rare exposures are expected, and updating terminology to include descriptive pregnancy safety studies. These methodological updates affect how sponsors and investigators design and document postapproval pregnancy safety investigations.

Final FDA Guidance for Pregnancy Safety Studies

On May 11, 2026 the FDA published a final guidance called "Postapproval Pregnancy Safety Studies" that gives recommendations to drug sponsors and investigators on how to design studies that assess safety outcomes in pregnant women after a drug or biologic is approved. The guidance finalizes a draft originally issued on May 9, 2019 and is available to industry and investigators for immediate use.

Guidance Is Non-Binding and Deregulatory

FDA states the guidance reflects its current thinking but is not binding; sponsors may use alternative approaches if they meet statute and regulation requirements. FDA also assessed this action as an Executive Order 14192 deregulatory action and the guidance contains no new collections of information under the Paperwork Reduction Act.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
5/11/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML
Back to Federal Register

Take It Personal

Get Your Personalized Policy View

Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.

Already have an account? Sign in